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ABSTRACT 
Role of Lymphatic Endothelial Cell Caveolin-1 in Macromolecule Transport 
  
Bradley D. Upchurch 
Department of Biochemistry and Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Joseph M. Rutkowski 
Department of Medical Physiology 
Texas A&M Health Science Center 
 
 
 The lymphatic system is a network of capillaries, vessels, and nodes that span the length 
of our entire body. Lymphatic capillaries uptake immune cells, fluid, and macromolecules from 
the interstitium and transport this lymph through vessels to lymph nodes for immune regulation 
and tissue fluid balance ultimately returning it to the blood vasculature. How fluid and solutes 
enter lymphatic capillaries has long been viewed as a passive paracellular mechanism in which 
macromolecules and fluid enter through valve-like openings in the loosely overlapped cell-cell 
junctions of lymphatic capillaries. Recent studies have demonstrated that lymphatic endothelial 
cells (LECs) may utilize pore formation with membrane caveolae as an active transcellular 
pathway to uptake macromolecules from the interstitium. Caveolin-1 is a protein required for the 
formation of caveolae and transcellular transport processes. We hypothesized that LECs utilize 
active caveolae to regulate lymphatic solute transport. To allow us to test our hypothesis, methods 
for primary LEC isolations and lymphatic vessel isolations had to be developed, established, and 
successfully tested. To test our hypothesis, we utilized a transgenic mouse carrying loxP sites 
flanking exon 3 of the Cav-1 gene. When crossed with mice expressing the enzyme Cre 
recombinase specifically in LECs, we generated mice lacking caveolin-1 in lymphatic 
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endothelium, and, therefore, LECs incapable of forming caveolae. We utilized this mouse to 
identify changes in lymphatic uptake and transport of macromolecules over a range of sizes in 
vivo. We isolated and perfused lymphatic vessels from these mice to quantify changes in vessel 
permeability as a function of solute size. In vitro, LECs from these mice, were cultured into 
monolayers to demonstrate active barrier function to macromolecules. Our data thus identify 
mechanisms of lymphatic transport that actively regulate solute transport with implications in 
antigen transport and immune maintenance. 
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NOMENCLATURE 
 
BEC  Blood Endothelial Cell 
Cav-1  Caveolin-1 
ECM  Extracellular Matrix 
eNOS  Endothelial Nitric-Oxide Synthase 
FLOX  Lymphatic Specific Deletion of Caveolin-1 
IFP  Interstitial Fluid Pressure 
kDa  Kilodaltons 
KO  Knock-out 
LEC  Lymphatic Endothelial Cell 
NO  Nitric oxide 
WT  Wild Type 
C  Initial Concentration of Dextran 
Js  Flux 
Jv  Starling Force 
Lp  Permeability 
Π  Osmotic Pressure 
σ  Osmotic Reflection 
P  Hydrostatic Pressure 
Peff  Effective Permeability 
S  Surface Area 
V  Volume 
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CHAPTER I 
INTRODUCTION 
 
Overview of Lymphatic System and Transport 
The lymphatic system is vital to our health by directing and controlling the interactions 
between ourselves and the environment that surrounds us (1). A major role of the lymphatic system 
is to absorb fluid that regularly extravasates from the blood vasculature (2). This fluid is 
extravasated due to hydrostatic and osmotic pressure differences and collects in the interstitial 
space also known as the interstitium (2). If this interstitial fluid is not sufficiently evacuated by 
lymphatics, it leads to a medical condition called lymphedema (3). Lymphatic vessels, specifically 
initial lymphatic capillaries, are responsible for removing this fluid and protein from the 
interstitium to maintain interstitial hydrostatic and osmotic pressure balance (2). Lymph vessels 
collect this fluid and protein, now called lymph, and return the lymph back into blood circulation 
for the important purpose of fluid balance and homeostasis (2). In this capacity, the lymphatic 
vasculature also regulates immune clearance and local immune interactions accomplished by 
immune cell and antigen trafficking, transport, and delivery to the lymph nodes for interaction. 
The system’s roles in fluid balance and immune regulations are tightly coupled, indeed 
inseparable, during acute and chronic inflammation (see Appendix for an authored review of the 
subject). While understanding lymphatic transport has clear impacts on immune function, this 
project focuses specifically on the critical role of lymphatics in macromolecule transport (4). 
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Lymphatic-Interstitial Interface 
While larger lymphatic vessels contain smooth muscle to aid in fluid propulsion, the initial 
lymphatic capillaries are not surrounded by smooth muscle and are in a partially collapsed state 
dependent on interstitial fluid pressure and extracellular matrix (ECM) compliance (5). The 
capillaries are also made up of a continuous layer of lymphatic endothelial cells (LECs) that do 
not contain any perforations (6, 7), lack baseline membranes (8), and tend to line up end to end or 
slightly overlapping meaning they do not have tight end-to-end junctions (6, 7, 9). To envision 
these junctions, Baluk and colleagues have described this interface as a series of buttons and 
zippers (10). This structure tends to favor paracellular permeability for lymphatics to fulfill as the 
preferred route of macromolecule transport from peripheral tissues. 
 Paracellular transport is the transport of fluid and molecules between cell-cell contacts that 
was originally found using an electron microscope looking at rat blood vessel structures (11). In 
lymphatic vessels, paracellular transport is controlled by anchoring filaments, similar in structure 
to elastin (12), that attach the basal lamina to the nearby extracellular matrix collagen fibers that 
expand the luminal volume in response to interstitial stress to take in more fluid into the vessels 
(5, 13-16). Fundamentally, fluid from the interstitial space can be pushed through the cell to cell 
junctions, but the overlapping nature of these junctions prohibit retrograde flow of the lymph back 
into the interstitium (5, 13, 16). Lymph is forced into the vessels by what is called Starling forces 
that are additive hydrostatic and oncotic forces that cause the movement of fluid across a capillary 
membrane that can be described by equation 1, below, originally derived to describe blood 
capillary extravasation. 
1. 𝐽𝑣 = 𝐿𝑝 &' (	∆𝑃 − 𝜎∆𝜋)1 
 
                                                
1 Terms in the equation 1 are defined in the Nomenclature section on page 5. 
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Cells can control permeability to fluid and molecules in constant hydrostatic and oncotic 
pressure conditions through the use of either paracellular transport or transcytosis. Furthermore, 
when Starling forces differential is high between the interstitium and the lymphatic lumen, more 
fluid and macromolecules are forced across the lymphatic barrier and into the cell by paracellular 
transport. It is a misconception to think of open lymphatic capillaries as having luminal hydrostatic 
and osmotic pressures equal to the interstitium. Downstream lymphatic vessel pumping provides 
a subtle pressure gradient for entry, and the vessel wall, and any openings therein, provide a 
reflection coefficient for solute size-dependent uptake. 
 The second mechanism of transport across an endothelial barrier is transcellular transport 
or transcytosis. Transcytosis is the movement of fluid and molecules across membranes using the 
process of endocytosis (6, 7, 17).  Using more extensively studied blood endothelium as a model 
of barrier function, studies have shown that blood capillaries utilize transcellular pathways to 
uptake macromolecules from the interstitium into the blood vasculature lumen (18). 
Macromolecules, including albumin, are unable to be transported through the small overlapping 
cell-cell junctions because they exceed a 3 nm globular structure and are instead specifically bound 
and transcytotically transported or generically taken up through non-specific endocytosis. These 
processes utilize caveolae which are localized in the cell membrane and consist of high levels of a 
protein called caveolin-1 (among others) (18, 19). Studies have also shown that when there is an 
increase in pressure in the interstitium, transcytosis increases to combat the increase in transmural 
pressure (20, 21). Increased blood pressure, or a lack of pore formation in blood endothelium 
likewise increase extravasation.  (22, 23). The relative ease of paracellular flux into lymphatic 
capillaries has previously discounted transcellular mechanisms in LECs (24). However, the 
continuous layer of LECs that make up lymphatic capillaries are full of 50-100 nm caveolar 
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invaginations that function in transporting large and small soluble macromolecules across the 
membrane into lymphatic capillaries which is defined as transcytosis or endocytosis (25-28); 
recent studies have shown that the lymphatic endothelium is not simply a passive barrier but has 
active transport capabilities for macromolecule transport (29-31). Most recently, a study was 
conducted that specifically tested the importance of intracellular transport (transcytosis) in 
lymphatic endothelial cells and successfully showed that transcytosis is an important pathway for 
lipid and solute transport in lymphatic endothelial cells (24). While this data is enlightening, we 
are interested in determining what protein is important for lymphatic transcytosis. To answer this, 
we will be focusing on Caveolin-1 found in caveolae. 
 
Caveolae and Caveolin-1 
 Caveolae have been characterized as crucial structures for transcytosis (27). Caveolar 
membranes are omega-shaped lipid rafts composed of cholesterol and sphingolipids and multiple 
structural proteins with some, the family of Caveolins (including Caveolin-1, Caveolin-2, and 
Caveolin-3), being specific to caveolar structures. While the makeup of caveolae vary from cell to 
cell, genetic studies have identified that the 21-24 kDa scaffolding protein Caveolin-1 is the single 
protein absolutely requisite for caveolae formation (32-37). As the essential protein for caveolar 
function, this project seeks to understand the importance of Cav-1 in transcytosis and lymphatic 
fluid transport. 
 Most of the experiments in the paper will be dealing with wild type (WT) mice versus 
Caveolin-1 KO mice specifically in lymphatics (Cav-1flox/flox) and globally (KO). These mice were 
created using a Cre-floxP system called Cre-Lox recombination. In this system, in floxP sites flank 
the gene of interest and with the addition of the Cre recombinase enzyme, the Cre-recombinase 
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proceeds bind to the loxP site and loop out the gene of interest creating a KO. An animation of the 
construction of these strains can be seen in Figure 1. Cav-1 protein is then absent from lymphatic 
endothelium of Floxed mice (Figure 2).   
 
Figure 1. Creation of CAV-1 KO Mouse. Here we used Cre-Lox recombination to create CAV-1 
KO mice. Essentially, the Cre, when added, attaches to the loxP site flanking the gene of interest 
and forces the DNA to loop out the gene of interest leaving the mouse a KO. 
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Figure 2. Caveolin-1 Levels in WT and FLOX lymphatic endothelial cells. Liver sections were 
visualized for lymphatic vessels as hepatocytes express little Caveolin-1. A) Caveolin-1 (red) co-
localizes with lymphatic endothelial cells (LYVE-1; green) making an orange/yellow color. B) 
Only the green LYVE-1 label is seen in in FLOX LECs because there is no Cav-1 present in 
lymphatics. 
 
Notable Cav-1 KO phenotypes are 1) organisms are still viable and while they show trouble 
executing endocytosis, the LECs show hyperproliferation (indicating tumor suppressor activity) 
and loss of caveolin-2 expression (38, 39) and 2) KO mice exhibit hyperpermeability (40). The 
fact that Cav-1 KO mice show hyperpermeability is interesting because the mice lack caveolae, 
which should mean that they lack the ability to execute transcytosis which should mean a decrease 
in permeability. But, hyperpermeability is observed meaning an increase in paracellular transport 
must be counteracting the loss of transcellular transport (40).  
 This study focuses on successfully developing methods for isolating primary lymphatic 
endothelial cells and isolation of intact lymphatic vessels for permeability studies to more 
accurately study the role of lymphatic caveolar transport in lymphatic macromolecular transport 
functions.   
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CHAPTER II 
MATERIALS AND METHODS 
 
Lymphatic Patterning and Morphology 
 Ears were taken from mice with the genotypes wild type (WT), lymphatic specific Cav-1 
knock out (FLOX), and global Cav-1 knock out (KO). These ears were then carefully dissected, 
separating the front and rear halves, and placed in a well in a 96 well flat bottomed plate. After 
splitting, the ears were incubated in 150 µL of anti-mouse LYVE1 antibody (1:200 dilution; R&D 
Systems) for 24 hours in a plate rocker in the 4 oC refrigerator. The ears were then taken out of the 
anti-mouse LYVE1 and washed two times in 150 µL of PBS before being transferred to 150 µL of 
the Donkey anti-goat (1:400 dilution; Life Technologies) secondary antibody for 24 hours in the 
4 oC refrigerator. After the 24-hour incubation, the ears were then washed twice in 150 µL of PBS 
before being mounted on microscope slides. The slides were then imaged under a fluorescent 
microscope and analyzed for vessel width, length, and number of branch points using ImageJ 
software. 
 
In Vivo Dextran Injections 
 Using two 3/10 cc syringes, a mouse was injected in both of its hind footpads with 20 µL 
of two mixtures of fluorescent dextrans. Mixture 1 was composed of a 3 kDa Fluorescein dextran 
and a 70 kDa Texas Red dextran that were each at 2 mg/mL final concentration. Mixture 2 
contained a 70 kDa Texas Red dextran and a 2,000 kDa Fluorescein dextran that were each at 2 
mg/mL final concentration. Figure 3 shows the injection site and lymphatic travel. 
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Figure 3. Footpad Injection Method. This figure shows the injection site and procedure along 
with the dextran pathway of travel through the lymphatic system. 
 
  All dextrans were molecular probes from Life Technologies. Injections on the mice were 
done under isoflurane anesthesia. Forty-five minutes after injection, the mice were sacrificed and 
the tissues taken included: a skin sample from the footpad, inguinal LN, popliteal LN, and 
axillary LN. These tissues were then homogenized in a Fisher Scientific Bead Mill 24 for 1 
minute in 1 mL tubes with 100 µL of Radioimmunoprecipitation assay (RIPA) buffer and 0.1 
mm zirconia/silica tissue disruption beads.  After homogenization, the samples were centrifuged 
at 21.1 xg for 10 minutes. Next, 50 µL of each sample were pipetted into a well on a 96 well 
plate to assess fluorescence levels. After fluorescence levels were determined, 2 µL of the 
samples and 23 µL of RIPA buffer were added to 200 µL of BCA reagents from a Thermo 
Scientific Pierce BCA Protein Assay Kit and incubated for 15-30 minutes and analyzed for 
protein concentration. The results are expressed as a ratio of sample fluorescence to protein 
concentration.  
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Primary LEC Isolation 
 Five mice were sacrificed to obtain the popliteal, inguinal, axillary, and brachial lymph 
nodes as well as the intestinal mesentery and diaphragm. These tissues were then minced for 10 
minutes in an autoclaved 10 mL beaker. The minced tissue was then digested for one hour in a 
37oC shaking water bath in an enzyme digestion solution containing 10 mL of digestion buffer, 50 
mg Sigma-Aldrich Collagenase D, 100 mg Fisher BioReagents Bovine Serum Albumin (Fraction 
V), 10 mg Sigma Dispase II, and 1 mg of Roche Liberase DH Research Grade. The digestion 
buffer consists of HEPES buffer (100 µM), NaCl (120 mM), KCl (50 mM), Glucose (5 mM), 
CaCl2 (1 mM), and water. After digestion was complete, the cells were centrifuged for 5 minutes 
at 500 xg. The layer of fat that accumulated at the top was then aspirated off. The cells were then 
resuspended in the digestion solution and filtered through a 100 µm filter top with an addition of 
10 mL of basal DMEM. The cells were then centrifuged for 10 min at 300 xg, and the media was 
aspirated off. Centrifugation and aspiration were then repeated. After aspiration, the pellet of cells 
was resuspended into 1 mL of basal DMEM in a 1.5 mL Eppendorf tube. Next, 10 µL of Biotin 
Rat Anti-Mouse CD31 (0.5 mg/mL) antibody were added to the cells. The cells were then 
incubated on a circular rotator for 60 min. After incubation, the cells were centrifuged at 6.1 xg 
for 5 min, and the media was aspirated off to remove unbound antibody while the cells were 
resuspended in 1 mL of basal DMEM. This centrifugation and aspiration was repeated two more 
times. The cells were then resuspended in 1 mL of basal DMEM and 10 µL of Invitrongen 
Dynabeads M-280 Streptavidin (10 mg/mL) magnetic beads were added to the cells. Again, the 
cells were incubated on a circular rotator, but this time for 40 min. After incubation, the cells were 
placed in a magnetic chamber for 2 minutes with minor movement while the magnetic beads 
collected near the side of the Eppendorf tube. The extra basal media was pipetted off, and the cells 
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were resuspended in 1 mL of basal media. This step is repeated two more times. But, on the last 
aspiration, the cells are resuspended in 1 mL of 10% Fetal Bovine Serum (FBS) full media 
supplemented with VEGF-C (50 ng/mL). The resuspended cells were then added to a collagen 
coated 60 mm plate along with 3 mL of 10% FBS +VEGF-C and incubated at 37oC with 5% CO2 
for 24 hours. After 24 hours, the media was changed. Media changes continued every 48 hours for 
1 week or until 80-100% confluency. 
 Once the cells reached 80-100% confluency, flow sorting was used to separate out true 
LECs from fibroblasts. In this step, cells were trypsinized with 1 mL of trypsin and centrifuged at 
600 xg for 5 minutes. The cells were then resuspended into 1 mL of FACS buffer (PBS+0.5% 
FBS). After resuspension, 30 µL of cells were added into three Eppendorf tubes labeled negative 
control, LYVE-1 positive, CD-31 positive, and the remaining cells became the sample tube. After 
distribution, the cells were centrifuged at 6.2 xg for 1 minute and aspirated and resuspended in 
their corresponding antibody solution. The negative tube had cells resuspended in 100 µL of FACS 
buffer, while the LYVE-1 and CD-31 tubes contained 100 µL of anti-mouse LYVE-1 (1:200) and 
anti-mouse CD-31 (1:400). The sample tube cells were resuspended in 100 µL of an antibody 
solution containing both anti-mouse LYVE-1 and anti-mouse CD-31. The LYVE-1 antibody used 
a Thermo Fisher Alexa Fluor 488 nm dye, while the CD-31 antibody used a Thermo Fisher 
Allophycocyanin (APC) 600 nm dye. After 10 minutes of incubation, the cells were spun down 
again and resuspended in FACS buffer and filtered. After filtering, the cells were centrifuged and 
resuspended in full media and sorted using a BD FACSAria II system. Cells that were positive for 
both CD31 and LYVE-1 were isolated and utilized as LECs. The sorted cells were then seeded 
into 6.5 mm transwell inserts at a concentration of 60,000 cells/ cm2.  
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Primary LEC Fluorescent Morphology 
 LECs were isolated and cultured following the methods from Primary LEC Isolation. After 
12 days of culturing in 20% FBS, the cells were fixed by adding 1 mL of chilled 100% methanol 
to the cells on ice for 2 minutes. The methanol was then aspirated off and 900 µL of PBS and 100 
µL of FBS were added to the plate along with an anti-mouse LYVE-1 antibody (R&D Systems) at 
a 1:200 dilution factor. The cells were then incubated overnight in the 4oC refrigerator. LYVE-1 
was visualized with a Donkey anti-goat secondary antibody (1:400; Life Technologies). DAPI 
(4',6-diamidino-2-phenylindole- a fluorescent stain) was then added to the cells to help visualize 
each individual cell nuclei. A fluorescent microscope was then used to visualize the cells. 
 
LEC Transwell Transport Permeability Assay 
 We closely followed the protocol for the Endothelial Permeability Assay used by the 
Swartz and Rutkowski labs (24, 29, 41). The LECs from WT and FLOX mice that were sorted 
using flow cytometry were then seeded into a 3 µm pore sized 6.5 mm Corning Transwell insert. 
The cells were then grown in 20% FBS+VEGF-C until a full confluent monolayer was observed 
(96-120 hours). Once confluent, a dextran solution containing a Texas Red 3 kDa (1 mg/mL) and 
a Fluorescein 2,000 kDa (2 mg/mL) was added to the transwell insert at a concentration of 10 
µg/mL. After 4 hours, 70 µL was taken from the top of the insert and the media below and run for 
fluorescence. Permeability was calculated as effective permeability (Equation 2) and relative 
effective permeability (Equation 3). 
2. 𝑃122 = 34∆5∗& 
 
 
3. 𝑃7189:;<1 = =>??	(@,BBB	CDE)=>??	(F	CDE)  
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These transwell experiments are meant to model initial lymphatic capillaries uptake of fluid 
and macromolecules from the interstitium at the lymphatic-interstitial interface.  
 
Lymphatic Vessel Isolation and Permeability Study 
 One mouse was sacrificed and dissected so that the skin section with the inguinal and 
axillary LNs were openly viewed. This set up can be seen in Figure 4. The tissue was covered with 
Krebs-Henseleit (KH) buffer +1% Bovine Serum Albumin (BSA) to balance the osmolarity. Then, 
using a Zeiss AxioCam MRc microscope, lymphatic vessels were found by finding a bundle of an 
artery and a vein that then has two lymphatic vessels on either side. The lymphatic vessel was 
dissected free from the fat and the artery/vein bundle. After the lymphatic vessel was dissected 
free and cleansed of remaining excess fat, it was sutured on the upstream end closest to the axillary 
LN using ophthalmic sutures. The vessel was then cut out and transferred to the cannulation 
chamber.  
The chamber contained 1 mL of the KH+1% BSA buffer solution and a cannulation pipet 
with a bore size of 60 µm. The vessel was then taken and attached to the cannulation pipet. Once 
attached, the vessel was sutured to the pipet to ensure that it would not slip of the end when 
pressurized. Next, the original suture on the free end was cut off and sutured again. Lastly, the 
vessel was pressurized at 3 cm with two different dextran solutions. Mix 1 contained a 3 kDa Texas 
Red dextran (1 mg/mL) and a 2,000 kDa Fluorescein dextran (2 mg/mL), while Mix 2 consisted 
of a 70 kDa Texas Red dextran (2 mg/mL) and a 2,000 kDa Fluorescein dextran (2 mg/mL). Lastly, 
10 µL of the chamber solution was taken every 10 minutes for an hour and analyzed using 
fluorescence. This entire vessel isolation set up can be seen in Figure 4. Vessel Isolation 
experiments were conducted to model the transport of fluid and macromolecules in larger 
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lymphatic vessels in between lymph nodes. In future experiments, this isolated vessel experiment 
could be used to measure vascular tone. 
 
Figure 4. Lymphatic Vessel Isolation and Cannulation. A) One mouse was sacrificed and pinned 
so that the inguinal-axillary lymphatic pathway was visible. The pathway is labeled with a red 
arrow. B) The red structure is an artery while the very faint but clear colored tube is the 
lymphatic vessel of interest and is labeled with a red arrow. C) Two cannulation pipets (60 µm 
radius) are connected by the lymphatic structure. D) A full vessel is isolated, sutured, cannulated, 
and pressurized with a fluorescent dextran mixture. 
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CHAPTER III 
RESULTS 
 
Lymphatic Patterning and Morphology 
Wild type (WT) and Cav-1flox/flox (FLOX) ears showed normal lymphatic architecture and 
patterning, while Cav-1 global knock out (KO) mice showed slightly hyperplastic lymphatic 
vessels (Figure 5). After quantification, WT and FLOX lymphatics had similar branches per vessel 
length and average vessel widths, while KO lymphatics showed a tendency to increase in both 
branches per vessel length and average vessel width [n=2: p=0.119] (Figure 6). Overall, there are 
no statistically significant differences in lymphatic patterning and morphology in FLOX mice. 
 
Figure 5. Lymphatic Patterning and Morphology. Mouse ears were fluorescently stained and 
imaged using anti-LYVE1 (1o) and donkey anti-goat (2o)  
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Figure 6. Quantification of Lymphatic Patterning and Morphology. ImageJ software was used to 
analyze each genotype (n=2). No statistically significant changes were observed. 
 
In vivo Dextran Injections 
 After injection of the tissues with the different dextran mixtures, the data was collected 
using a ratio of fluorescence to protein concentration. After analysis, it was observed that there are 
no statistically significant changes in transport based on genotype or dextran size. All dextrans 
seemed to be taken up and transported with similar efficiencies creating a decaying trend beginning 
with the skin and ending with the axillary node (Figure 7). However, although there is no difference 
observed in the overall uptake and transport, the two lymphatic functions are present in vivo. In 
the first, lymphatic capillaries are taking up the injected dextran from the skin. In the second, this 
dextran in the lymph must be transported far downstream through the series of lymph nodes. We 
thus utilized two separate lymphatic models ex vivo to mimic initial uptake by capillaries and 
transport by larger vessels using transwell experiments and vessel isolations, respectively. 
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Figure 7. Injection Results. Three different dextrans were used and each dextran was tested in 
three different mouse genotypes: WT, FLOX (CAV-1 locally deleted in lymphatics), and KO 
(CAV-1 globally deleted).  
 
 
Primary LEC Isolation and Morphology 
After staining with the LYVE-1 antibody and DAPI, the cells imaged were seen to form 
into tube structures (Figure 8). 
 
Figure 8. Lymphatic Tube Morphology: Green fluorescence is the LYVE-1 stain that illuminated 
LECs, while the blue fluorescence is the DAPI stain that illuminated nuclei. A) Imaged at 10X. 
Showing multiple tube structures connecting to each other to make a single tube. B) Imaged at 
20X. Showing two tails of tubes splitting off. C&D) Imaged at 40X.  
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The LECs grew as if they were in vivo showing the native tubular structure that is rarely 
seen on cultured plates (Figure 8). The green fluorescence is the LYVE-1 antibody that stains 
LECs, while the blue fluorescence is the DAPI stain that binds to DNA to visualize cellular nuclei. 
Therefore, the background blue dots of fluorescence are nuclei of other cells that are growing on 
the plate that have not been tagged by the LYVE-1 antibody because they are not LECs, but most 
likely fibroblasts. But, in the LEC tube structures we can clearly see at 40X magnification that the 
tube is made up of many LECs that have grown together in tubes rather than spreading out in a 
planar fashion demonstrating a “cobble stone” growth pattern. This shows that when LECs are 
cultured on top of a bed of contaminating fibroblasts, they revert to growing as if in vivo to reach 
out and connect with other LEC cells. 
 However, the cell population from Figure 8 were not a pure LEC population. To obtain a 
pure LEC population, the LEC isolation protocol from the Material and Methods Section was 
conducted and cells were subsequently flow sorted after one week of culture.  
 
Figure 9. LEC Flow Sorting Results. A pure population of LECs are indicated above being both 
LYVE-1 and CD-31 positive. 
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LYVE-1 levels indicate the presence of lymphatic specific cells, while CD-31 levels 
indicate endothelial cells. So, our population of lymphatic endothelial cells should be both highly 
positive in both LYVE-1 and CD-31, while contaminating blood endothelial cells (BECs) will be 
CD-31 positive but not LYVE-1 positive (Figure 9). These results clearly indicate that we were 
successfully able to isolate a pure culture of LECs (Figure 9). However, initial isolated LECs were 
merely wildtypes for a proof-of-concept study. So, another isolation and sort was conducted to 
obtain pure LECs from WT, FLOX, and KO genotypes. Pure LEC populations were obtained from 
all three genotypes (Figure 10). We were able to sort 61,000 LECs from WT culture, 80,000 LECs 
from FLOX culture, and 150,000 LECs from KO culture. 
 
Figure 10. Flow Sort Results from WT, FLOX, and KO cell types. Pure populations of LECs 
were sorted for all three genotypes by finding cells that were both LYVE-1 and CD-31 positive. 
The purple area represents LECs, while the blue area represents contaminating BECs. The KO 
genotype had the most LECs with 150,00 while WT and FLOX had 60,000 and 80,000 cells 
respectively. 
 
 
LEC Transwell Transport Permeability Assay 
 The transwell experiments were conducted to model the initial uptake of macromolecules 
and fluid from the interstitium by capillaries. The effective permeability data from both the 3 
kDa and 2,000 kDa dextrans showed a slight increase in WT cells over FLOX cells, but this 
increase is not statistically significant (Figure 11A-B). Also, a relative permeability analysis was 
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graphed to normalize the 2,000 kDa dextran to the 3 kDa dextran to control for passive barrier 
integrity (Figure 11C). It does show that the relative permeability of FLOX is higher than WT, 
but this is statistically insignificant (Figure 11C). Also, the relative permeability data shows that 
the 2,000 kDa dextran had an 8 to 10-fold concentration difference than 3 kDa (Figure 11C). 
However, it does not seem congruent that a 2,000 kDa dextran will travel through cells more 
quickly and efficiently than a 3 kDa dextran. This is most likely due to the fact that the 3 kDa 
dextran we use is attached to 0.75 dye particles per molecule of dextran while the 2,000 kDa 
dextran has, on average, 75 dye particle attached to each molecule of dextran. So, the 
fluorescence may not be giving us the most accurate concentration measurements. Future 
experiments will correct for this finding. Lastly, our culture conditions and times likely did not 
produce enough cells for a reliable monolayer, essentially lending these results to be a proof of 
concept study. This is how future experiments in this project will be analyzed with full confluent 
monolayers.  
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Figure 11. Effective Permeability Results. A) Effective Permeability of 3 kDa dextrans in WT 
and FLOX cultured cells measured by effective permeability (Peff) seen in Equation 2 with units 
cm/sec. B) Effective Permeability of 2,000 kDa dextran in WT and FLOX cultured cells 
measured by effective permeability (Peff) seen in Equation 2 with units cm/sec. C) Relative 
Effective Permeability used to normalize data to 3 kDa to control for passive barrier integrity.  
 
 
Lymphatic Vessel Isolation and Permeability Study 
 We were successfully able to isolate and perfuse a lymphatic vessel running from the 
inguinal and axillary lymph nodes from the flank of a mouse (Figure 12). A lymphatic vessel 
section measuring 4 mm in length was successfully isolated and cannulated (Figure 12A). The 
fluorescent image of the same perfused vessel shows that the fluorescence is defined to the 
membrane of the lymphatic vessel explaining that the vessel is undamaged and functional (Figure 
12B). If the vessel was damaged, fluorescence would be visible outside of the lymphatic vessel 
membrane in the chamber solution surrounding the vessel. 
 26 
 
Figure 12. Lymphatic Vessel Isolation. A) A lymphatic vessel (4 mm) is successfully cannulated 
and pressurized with a fluorescent dextran solution and imaged under white light. B) The same 
lymphatic vessel from panel A is being imaged using fluorescence. 
 
 A permeability study was also conducted to model the transport of macromolecules and 
fluid in larger lymphatic vessels in between lymph nodes. The kinetic data, while slightly 
skewed, showed the general trend that we expected (Figure 13). We expected a slow upward 
trend in both WT and FLOX vessels that was generally observed. However, these results are 
substantially skewed. But, this is not critical. These experiments were essentially “proof of 
concept” studies to pave the way for future experiments in the lab with this very detailed and 
difficult vessel isolation protocol.  
 
Figure 13. Isolated Vessel Permeability Results. Dextran or Fluorescent concentration per area 
was measured every 10 minutes for 1 hour. 
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CHAPTER IV 
DISCUSSION 
 
This study focuses on developing protocols for primary LEC isolation and the isolation of 
intact lymphatic vessels for permeability studies to quantify the role of caveolae in lymphatic 
macromolecule uptake and transport. These goals were accomplished. 
Lymphatic patterning and morphology was an important first experiment because if the 
architecture of the lymphatic vessels looked vastly different, the subsequent results may be a 
product of lymphatic structure density (an increase vessel wall surface area ‘S’ from Starling’s 
equation) and not specifically lymphatic active versus passive transport pathways. The ear 
lymphatic patterning showed no statistically significant differences in LEC-specific FLOX mice, 
important for comparing an in vivo data. While the KO ears did seem to be slightly hyperplastic 
this was expected. In KO mice, the entire mouse lacks Cav-1 meaning that the blood vasculature 
will be much more “leaky” (38, 40) and increased interstitial pressure is expected. Increased IFP 
forces the lymphatic vessels to slightly expand (42). But, there were no measurable differences in 
Cav-1 KO tissues meaning that any results from the subsequent experiments could be attributed to 
the presence or lack of Cav-1 and not the lymphatic architecture. 
This led to the first in vivo study utilizing footpad injections with differing sized dextrans 
to measure any transport differences between the three mouse genotypes: WT (Cre-), FLOX 
(Cre+), and KO. The nomenclature of Cre-/Cre+ indicates whether the Cre recombinase enzyme 
was ever introduced into the strain. If it was, then Cav-1 was locally deleted in lymphatics, if not, 
Cav-1 was wild type. Three different sized dextrans were used to test the mouse’s differing abilities 
to uptake and transport the dextrans through the lymphatics. The sizes were chosen specifically 
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because of their Stoke’s radii. For endothelial layers, solutes with a Stoke’s radii of under 3 nm 
usually travel paracellularly, while molecules with Stoke’s radii above 3 nm, like albumin, require 
transcytosis for appreciable transport (43). In this experiment, the 3 kDa dextran has a Stoke’s 
radius that is much smaller than 3 nm which allows it to easily travel paracellularly while the 70 
and 2,000 kDa dextrans have Stoke’s radii of 6.4 and 26.89 nm respectively indicating that they 
require active transport across the membrane (44). So, for WT mice with normal levels of Cav-1, 
we expect for all the dextrans to be able to be taken up and transported to the axillary because the 
mice are capable of transcytosis. On the other hand, FLOX mice lack Cav-1 in lymphatics and 
therefore are incapable of active transport, which we expect would increase paracellular flux and 
increase dextran transport. An increase in overall lymphatic transport in in cells lacking 
transcytosis seems paradoxical, but when transcytosis is blocked, this forces the loose overlapping 
junctions to open much wider than usual allowing large molecules to be taken in. This trend should 
also be evident in KO mice that have Cav-1 globally deleted because interstitial pressure will 
increase thus forcing more fluid and macromolecules to be transported transcellularly. The highest 
concentration of dextrans was found in the skin, while a decaying trend continued to the axillary 
LN across all three dextran sizes and all three genotypes. These results seem incongruent because 
if you inject into the footpad, you should expect that the highest level of dextrans will stay in the 
footpad especially with only 45 minutes given for transport. Also, the axillary LN levels of the 
dextrans were the lowest because it was the farthest lymph node from the injection site. Although 
a small hump was observed in the 2,000 kDa popliteal category in FLOXED mice, this was not 
statistically significant. Overall, there were no remarkable differences in trends between the 
genotypes and dextran sizes. This could possibly be explained by the fact that the paracellular 
transport pathway is successfully recovering the transport defects from Cav-1 deleted mice. Most 
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importantly, the study diverged to focus on the two specific models involved in the in vivo injection 
experiments: initial lymphatic uptake and vessel transport.  
To address the role of initial lymphatic uptake of capillaries, we moved our focus from in 
vivo to in vitro by specifically isolating and culturing LECs to test the transcellular flux of a LEC 
monolayer. Following our novel LEC Isolation Protocol rendered cultures that had LEC clusters 
but with some fibroblast contamination (which outgrow endothelial cells in culture). Although our 
culture was not a pure LEC population with the hallmark “cobble stone” morphology, we were 
able to observe interesting growth patterns in the LECs. In vitro, LECs are known to grow in a 
monolayer that when imaged looks like “cobble stones”, while in vivo they grow in tube structures 
forming capillaries and vessels. In our culture, we observed that our LECs grew as if they were in 
vivo forming tube structures on top of a monolayer of fibroblasts (Figure 8). The LEC tubes even 
were seen to split off into tails stretching out to other LEC clusters (Figure 8D), which is similar 
to their behavior in vivo. Although this growth patterning is rare in tissue culture, it did not render 
a pure LEC population. To obtain a pure LEC population, a flow sorting experiment was conducted 
and achieved (Figure 9). Since we are specifically interested in LECs, they are highly LYVE-1 
and CD-31 positive since they lymphatics and endothelial cells respectively. This means that P2 
in Figure 9 labeled as “LECs” was our pure population that would then be used for transcellular 
transport studies. However, we needed pure LECs from our three genotypes of interest, WT, 
FLOX, and KO, to test transcellular flux differences among the three genotypes. To accomplish 
this, another isolation and flow sort was done to isolate pure LECs from all three genotypes (Figure 
10) that were then used in transwell transport experiments. 
The transwell transport experiments focused on the change in flux between the monolayer 
of LECs. Similar to the in vitro dextran injection experiments, the chosen dextrans were 3 kDa and 
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2,000 kDa because the 3 kDa dextran should flow directly through the monolayer paracellularly 
like normal media due to its small Stoke’s radii, while the bulky 2,000 kDa dextran would require 
active transport to pass the monolayer barrier. The data was focused on a “proof of concept” study 
because there was insufficient time to grow a reliable monolayer. While the results indicate slights 
differences in the effective and relative permeabilities, they were not statistically significant 
(Figure 11). Future experiments will focus on utilizing transendothelial resistance data to ensure a 
reliable monolayer is present.  
Lastly, to test lymphatic vessel permeability in vivo more extensively than footpad 
injections, we developed a Lymphatic Vessel Isolation experimental protocol. This allowed us to 
take a living lymphatic vessel and test its permeability with differing dextran solutions. We were 
able to successfully isolate and perfuse an intact lymphatic vessel from the mouse flank and run 
permeability experiments (Figure 12&13). Since there was no dextran leakage in the fluorescent 
image, the lymphatic membrane was still intact allowing the vessel to behave as if it were still 
within the body (Figure 12B). This technique is extremely difficult and specialized – only a handful 
of groups worldwide successfully employ this method. The vessel isolation technique also opens 
up a new avenue to study lymphatic vessels in vivo. While the initial permeability study showed 
no novel observations, the procedure and analysis allows us to assess permeability in a novel way 
that will continue to be utilized in our lab. 
To test whether Cav-1 is a critical protein for transcellular transport, two protocols had to 
be developed: 1) Primary LEC Isolation and 2) Lymphatic Vessel Isolation. These protocols would 
provide an in vitro and an in vivo model for Cav-1 respectively and were extremely important for 
the success of the project. Both of the protocols were successfully developed and tested which 
allowed for this project to be studied in detail. While the Primary LEC Isolation protocol that we 
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developed may be a more widespread technique used in mouse lymphatic labs across the country, 
the success of our Lymphatic Vessel Isolation protocol put us in a category with only a select few 
labs worldwide that have accomplished this difficult task of isolating a live lymphatic vessel from 
a mouse. This accomplishment not only benefits this particular project, but it allows for our lab to 
use a rare novel technique that will bring consistent success. 
For future directions, we will focus on perfecting our transwell and permeability 
experiments. To do this, we must determine whether we have a consistent and reliable monolayer 
in our transwell plates. This will be accomplished by longer growth times as well as utilizing 
transendothelial resistance to quantify the growth of our monolayers. We will also continue to 
perfect our isolation vessel protocol to test if, in fact, mice lacking Cav-1 are more “leaky” than 
those that are WT. This could explain the results from our in vivo study (Figure 7). It is possible 
that in FLOX mice the initial lymphatics, there is an increase in uptake of macromolecules and 
fluid, while the larger vessels become “leaky” having a balancing out effect. 
Within the field of lymphatics, our data subtly supports the work of Triacca et. al. (2017). 
However, this project could have implications in not only uptake and transport but also in pumping 
due to the connections of Cav-1 to the signaling molecule NO involved in lymphatic vasculature 
permeability and pumping (45-48). Endothelial Nitric-Oxide Synthase (eNOS) specifically targets 
caveolin-1 which directly inhibits NO production by eNOS (48). This is relevant because eNOS is 
in charge of making the signaling molecule NO that is responsible for controlling vasomediators 
and vascular permeability (49-52). Nitric oxide (NO) could be controlling vascular permeability 
by changing cell morphology and cell junction structures, but the exact mechanism is unknown 
(45, 46). Overall, Caveolin-1 could be regulating cell permeability not only directly through 
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transcytosis but also indirectly by prohibiting the production of NO which in turn regulates 
vasculature permeability  (47). 
In conclusion, this study focused on the role of Caveolin-1 in transcellular transport of 
macromolecules. Our results corroborate the results of Triacca et. al. (2017) showing that 
transcellular transport is in fact important for lymphatic endothelial transport. We also suggest that 
this is specifically due to the presence of Cav-1 in the caveolae responsible for transcytosis which 
will be further studied with our pure LEC population and isolated vessels. Overall, the study was 
successful in developing two protocols that are vital for future research over the role of Cav-1 in 
macromolecule transport.  
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APPENDIX  
Lymphangiogenesis:	fuel,	smoke,	or	extinguisher	of	
inflammation’s	fire? 
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Abstract	
Lymphangiogenesis	 is	 a	 recognized	 hallmark	 of	 inflammatory	
processes	 in	 tissues	 and	 organs	 as	 diverse	 as	 the	 skin,	 heart,	
bowel,	 and	airways.	 In	 clinical	 and	animal	models	wherein	 the	
signaling	processes	of	lymphangiogenesis	are	manipulated,	most	
studies	demonstrate	that	an	expanded	lymphatic	vasculature	is	
necessary	 for	 the	resolution	of	 inflammation.	The	fundamental	
roles	 that	 lymphatics	 play	 in	 fluid	 clearance	 and	 immune	 cell	
trafficking	 from	 the	 periphery	 make	 these	 results	 seemingly	
obvious	 as	 a	 mechanism	 of	 alleviating	 locally	 inflamed	
environments:	 the	 lymphatics	 are	 simply	 providing	 a	 drain.	
Depending	 on	 the	 tissue	 site,	 lymphangiogenic	mechanism,	 or	
induction	 timeframe,	 however,	 evidence	 shows	 that	
inflammation-associated	 lymphangiogenesis	 (IAL)	 may	 worsen	
the	 pathology.	 Recent	 studies	 have	 identified	 lymphatic	 endothelial	 cells	 themselves	 to	 be	 local	
regulators	of	immune	cell	activity	and	its	consequential	phenotypes	–	a	more	active	role	in	inflammation	
regulation	than	previously	thought.	 Indeed,	results	focusing	on	the	immunocentric	roles	of	peripheral	
lymphatic	function	have	revealed	that	the	basic	drainage	task	of	lymphatic	vessels	is	a	complex	balance	
of	locally	processed	and	transported	anti- 
gens	as	well	as	interstitial	cytokine	and	immune	cell	signaling:	an	interplay	that	likely	defines	the	function	
of	 IAL.	This	review	will	summarize	the	 latest	 findings	on	how	IAL	 impacts	a	series	of	disease	states	 in	
various	tissues	in	both	preclinical	models	and	clinical	studies.	This	discussion	will	serve	to	highlight	some	
emerging	 areas	 of	 lymphatic	 research	 in	 an	 attempt	 to	 answer	 the	 question	 relevant	 to	 an	 array	 of	
scientists	and	clinicians	of	whether	IAL	helps	to	fuel	or	extinguish	inflammation. 
Keywords:	Vascular	endothelial	growth	factor	receptor-3,	lymphatic,	vascular	endothelial	growth	factor-
D,	metabolic	syndrome,	endometriosis,	hypertension 
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Impact	statement 
Inflammatory	progression	is	present	in	acute	
and	chronic	tissue	pathologies	throughout	the	
body.	Lymphatic	vessels	play	physiological	
roles	relevant	to	all	medical	fields	as	
important	regulators	of	fluid	balance,	immune	
cell	trafficking,	and	immune	identity.	
Lymphangiogenesis	is	often	concurrent	with	
inflammation	and	can	potentially	aide	or	
worsen	disease	progression.	How	new	
lymphatic	vessels	impact	inflammation	and	by	
which	mechanism	is	an	important	
consideration	in	current	and	future	clinical	
therapies	targeting	inflammation	and/or	
vasculogenesis.	This	review	identifies,	across	a	
range	of	tissue-specific	pathologies,	the	
current	understanding	of	inflammation-
associated	lymphangiogenesis	in	the	
progression	or	resolution	of	inflammation. 
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